AP2014007699A0 - Compositions and methods for treating hepatitis C virus - Google Patents
Compositions and methods for treating hepatitis C virusInfo
- Publication number
- AP2014007699A0 AP2014007699A0 AP2014007699A AP2014007699A AP2014007699A0 AP 2014007699 A0 AP2014007699 A0 AP 2014007699A0 AP 2014007699 A AP2014007699 A AP 2014007699A AP 2014007699 A AP2014007699 A AP 2014007699A AP 2014007699 A0 AP2014007699 A0 AP 2014007699A0
- Authority
- AP
- ARIPO
- Prior art keywords
- virus
- compositions
- methods
- treating hepatitis
- hepatitis
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161564500P | 2011-11-29 | 2011-11-29 | |
| PCT/US2012/055621 WO2013040492A2 (en) | 2011-09-16 | 2012-09-14 | Methods for treating hcv |
| US201261707459P | 2012-09-28 | 2012-09-28 | |
| US13/661,509 US20130109647A1 (en) | 2011-10-31 | 2012-10-26 | Methods and compositions for treating hepatitis c virus |
| PCT/US2012/066605 WO2013082003A1 (en) | 2011-11-29 | 2012-11-27 | Compositions and methods for treating hepatitis c virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2014007699A0 true AP2014007699A0 (en) | 2014-06-30 |
Family
ID=48803225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2014007699A AP2014007699A0 (en) | 2011-11-29 | 2012-11-27 | Compositions and methods for treating hepatitis C virus |
Country Status (4)
| Country | Link |
|---|---|
| AP (1) | AP2014007699A0 (en) |
| EC (1) | ECSP21087299A (en) |
| IL (1) | IL232889A (en) |
| MY (1) | MY187735A (en) |
-
2012
- 2012-11-27 AP AP2014007699A patent/AP2014007699A0/en unknown
- 2012-11-27 MY MYPI2014001520A patent/MY187735A/en unknown
-
2014
- 2014-05-29 IL IL232889A patent/IL232889A/en active IP Right Grant
-
2021
- 2021-12-02 EC ECSENADI202187299A patent/ECSP21087299A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL232889A (en) | 2016-07-31 |
| IL232889A0 (en) | 2014-07-31 |
| ECSP21087299A (en) | 2022-02-25 |
| MY187735A (en) | 2021-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201402609RA (en) | Compositions and methods for treating hepatitis c virus | |
| ZA201307914B (en) | Compositions and methods for inhibiting gene expression of hepatitis b virus | |
| IL221033A0 (en) | Hepatitis c virus inhibitors | |
| EP2575819A4 (en) | Hepatitis c virus inhibitors | |
| IL231515A (en) | Compositions for treating hcv | |
| ZA201306720B (en) | Hepatitis c virus inhibitors | |
| EP2757887A4 (en) | Pyrrolopyridinone compounds and methods for treating hiv | |
| IL229270B (en) | Hepatitis c virus inhibitors | |
| IL224298A (en) | Hepatitis c virus inhibitors | |
| EP2768517A4 (en) | Hepatitis c virus inhibitors | |
| ZA201404494B (en) | Method for treating hepatitis c virus infection using quercetin-containing compositions | |
| EP2603080A4 (en) | Hepatitis c virus inhibitors | |
| ZA201501752B (en) | Methods for treating hepatitis c | |
| ZA201309356B (en) | Hepatitis c virus inhibitors | |
| ZA201205547B (en) | Therapies for treating hepatitis c virus infection | |
| ZA201503458B (en) | Hepatitis c virus inhibitors | |
| EP2869821A4 (en) | Compositions and methods for treating and inhibiting viral infections | |
| ZA201501758B (en) | Methods for treating hepatitis c | |
| ZA201207226B (en) | Compositions and methods for treating viral diseases | |
| SG11201402899TA (en) | Methods and compositions for treating viral diseases | |
| PL2838903T3 (en) | Methods and compositions for treating viral infections | |
| LT2850075T (en) | Piperazine-piperidine compounds as hepatitis c virus inhibitors | |
| IL232889A0 (en) | Compositions and methods for treating hepatitis c virus | |
| EP2826486A4 (en) | Agent for the treatment of hepatitis c virus | |
| EP2747765A4 (en) | Compositions and methods for treating viral diseases |